Table 1.
Reimbursement recommendations of 9 European Union jurisdictions for NASs receiving EMA marketing authorization in accordance with regulation 726/2004 between January 1, 2008 and December 31, 2012.
| Jurisdiction (Agency) | Reimbursed | Reimbursed with restrictions | Not reimbursed | Proportion of medicines receiving marketing authorization to receive a recommendation at time of study (%) | Website |
|---|---|---|---|---|---|
| Belgium (Belgium Health Insurance Agency; INAMI) | Insured (Class 1) | N/A | Not reimbursed | 69 | www.inami.be |
| Insured (Class 2) | |||||
| England (National Institute for Health and Care Excellence; NICE) | Recommended | Optimized | Not recommended | 39 | www.nice.org.uk |
| France (French National Authority for Health; HAS) | Approved | Approved with restriction | Not recommended | 91 | www.has-sante.fr |
| Germany (Federal Joint Committee; G-BA) | Indication of a considerable additional benefit | 30 | www.english.g-ba.de | ||
| Hint of considerable additional benefit | |||||
| Proof of a significant additional benefit | |||||
| Minor additional benefit | |||||
| Additional benefit has not been proved | |||||
| Ireland (National Centre for Pharmacoeconomics; NCPE) | Reimbursement recommended | Reimbursement not recommended | 56 | www.ncpe.ie | |
| Reimbursement not recommended at submitted price | |||||
| Italy (Italian Medicines Agency; AIFA) | Reimbursed Class A | 67 | www.agenziafarmaco.gov.it | ||
| Reimbursed class H | |||||
| Netherlands (National Health Care Institute; ZiNL) | Insured (Annex 1A) | Insured with restrictions | Not recommended | 75 | www.zorginstituutnederland.nl |
| Insured (Annex 1B) | |||||
| Scotland (Scottish Medicines Consortium; SMC) | Accepted | Restricted | Not recommended | 77 | www.scottishmedicines.org.uk |
| Sweden (Dental and Pharmaceutical Benefits Agency; TLV) | General | Limitations | Not recommended | 61 | www.tlv.se |